Skip to Content

Apogee Therapeutics Inc APGE

Morningstar Rating
$50.31 −3.44 (6.40%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

APGE is trading at a 411% premium.
Price
$50.45
Fair Value
$23.94
Uncertainty
Extreme
1-Star Price
$677.45
5-Star Price
$16.27
Economic Moat
Ykr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APGE is a good fit for your portfolio.

Trading Information

Previous Close Price
$53.75
Day Range
$50.1954.59
52-Week Range
$14.1972.29
Bid/Ask
$50.25 / $50.31
Market Cap
$2.84 Bil
Volume/Avg
442,861 / 712,854

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
91

Valuation

Metric
APGE
Price/Earnings (Normalized)
Price/Book Value
2.96
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
APGE
Quick Ratio
37.87
Current Ratio
38.08
Interest Coverage
Quick Ratio
APGE

Profitability

Metric
APGE
Return on Assets (Normalized)
−24.57%
Return on Equity (Normalized)
−25.54%
Return on Invested Capital (Normalized)
−29.79%
Return on Assets
APGE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFzqbrrjkkNdgqq$586.1 Bil
VRTX
Vertex Pharmaceuticals IncQmjndglsYxfnlh$113.7 Bil
REGN
Regeneron Pharmaceuticals IncPhcbdxvzCckrpm$108.2 Bil
MRNA
Moderna IncVstmczbdLkm$50.9 Bil
ARGX
argenx SE ADRXyszkrrQzfzt$22.0 Bil
BNTX
BioNTech SE ADRCblhvcgnBlb$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncVtfyyjvlyPkwjry$18.9 Bil
BMRN
Biomarin Pharmaceutical IncNgyjrftLfxqxh$14.6 Bil
INCY
Incyte CorpYpkyvjdxDlzxssj$12.8 Bil
RPRX
Royalty Pharma PLC Class ANcsncfzdfDxcqftz$12.3 Bil

Sponsor Center